MetaVia (NASDAQ:MTVA) Announces Quarterly Earnings Results

MetaVia (NASDAQ:MTVA) released its quarterly earnings results on Thursday. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.08), FiscalAI reports.

MetaVia Stock Up 2.8%

Shares of MTVA stock traded up $0.04 during trading hours on Friday, hitting $1.49. 107,022 shares of the company were exchanged, compared to its average volume of 549,292. The firm has a market cap of $7.69 million, a PE ratio of -0.29 and a beta of 0.95. MetaVia has a 1 year low of $0.97 and a 1 year high of $19.03. The firm has a fifty day moving average of $1.72 and a 200 day moving average of $1.75.

Analyst Ratings Changes

Several analysts have recently issued reports on MTVA shares. HC Wainwright restated a “buy” rating on shares of MetaVia in a research report on Friday, July 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of MetaVia in a research note on Tuesday, July 21st. Finally, Wall Street Zen upgraded shares of MetaVia to a “sell” rating in a report on Saturday, June 20th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, MetaVia presently has an average rating of “Hold” and a consensus price target of $20.00.

Institutional Investors Weigh In On MetaVia

An institutional investor recently bought a new stake in MetaVia stock. Virtu Financial LLC purchased a new position in shares of MetaVia Inc. (NASDAQ:MTVA) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned about 0.14% of MetaVia as of its most recent filing with the Securities and Exchange Commission (SEC). 1.37% of the stock is owned by institutional investors and hedge funds.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.